Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SinoMab Bioscience Ltd. ( (HK:3681) ) has issued an update.
SinoMab BioScience Limited has announced that its board of directors will meet on 31 March 2025 to approve and publish the company’s final results for the year ended 31 December 2024. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and strategic direction.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a biotechnology company based in Hong Kong, focusing on the development of therapeutic products for the treatment of immunological diseases.
YTD Price Performance: 5.50%
Average Trading Volume: 171,580
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$1.26B
For detailed information about 3681 stock, go to TipRanks’ Stock Analysis page.